Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Zimmer Biomet Holdings ( (ZBH) ) has provided an announcement.
Zimmer Biomet announced a leadership change on April 28, 2026, as Chief Financial Officer and Executive Vice President – Finance, Operations and Supply Chain Suketu Upadhyay departed the company effective the same day to pursue another professional opportunity. The company stated that his resignation did not stem from any disagreement over financial reporting, internal controls or corporate practices.
To ensure continuity, Zimmer Biomet appointed Vice President, Controller and Chief Accounting Officer Paul Stellato as interim Chief Financial Officer, making him the principal financial and accounting officer while an internal and external search for a permanent successor proceeds. Stellato, a seasoned finance leader with more than two decades of experience at Zimmer Biomet, Xylem and ITT, will receive increased salary, bonus eligibility and incremental equity awards reflecting his expanded responsibilities during the transition.
Management highlighted Stellato’s role in advancing the company’s strategy since joining in 2022, including disciplined capital allocation tied to recent acquisitions and share repurchases, signaling an intent to maintain strategic and financial momentum despite the CFO change. The structured interim arrangement and clear succession process are designed to reassure investors and other stakeholders about the stability of Zimmer Biomet’s financial leadership and ongoing execution of its transformation agenda.
The most recent analyst rating on (ZBH) stock is a Hold with a $93.00 price target. To see the full list of analyst forecasts on Zimmer Biomet Holdings stock, see the ZBH Stock Forecast page.
Spark’s Take on ZBH Stock
According to Spark, TipRanks’ AI Analyst, ZBH is a Neutral.
The score is driven primarily by solid multi-year financial performance and strong cash generation, supported by earnings-call commitments to free cash flow growth and material buybacks. It is held back by margin and leverage watch items, tempered 2026 growth guidance with execution risk (salesforce transition and pricing pressure), and a mixed technical trend (below key longer-term moving averages with negative MACD).
To see Spark’s full report on ZBH stock, click here.
More about Zimmer Biomet Holdings
Zimmer Biomet Holdings is a global medical technology company focused on maximizing mobility and improving health through a comprehensive portfolio of orthopedic and related products, including integrated digital and robotic technologies that leverage data, analytics and artificial intelligence. With more than 90 years of industry presence, operations in over 25 countries and sales in more than 100, it positions itself as a trusted provider of high-quality solutions for patients and healthcare providers worldwide.
The company emphasizes a strategy of disciplined capital allocation, including acquisitions and share repurchases, to support its transformation and maintain competitiveness in the global medtech market.
Average Trading Volume: 2,130,642
Technical Sentiment Signal: Sell
Current Market Cap: $17.67B
For detailed information about ZBH stock, go to TipRanks’ Stock Analysis page.